title: [Biological therapy in idiopathic inflammatory myopathies].
abstract: Idiopathic inflammatory myopathies are systemic, immune-mediated diseases characterized by proximal, symmetrical, progressive muscle weakness. The aim of this work is to give an overview of the biological therapy used in the treatment of idiopathic inflammatory myopathies. The authors also focus on novel results in the therapy directed against the B- and T-cells. They emphasize the importance of new trials in these diseases which may lead to the introduction of novel therapeutic options in these disorders.
authors.affiliation: Debreceni Egyetem, Orvos- és Egészségtudományi Centrum Belgyógyászati Intézet, Klinikai Immunológia Tanszék Debrecen Móricz Zsigmond körút 22. 4032.
authors.forename: Levente
authors.initials: L
authors.lastname: Bodoki
authors.affiliation: Debreceni Egyetem, Orvos- és Egészségtudományi Centrum Belgyógyászati Intézet, Klinikai Immunológia Tanszék Debrecen Móricz Zsigmond körút 22. 4032.
authors.forename: Melinda
authors.initials: M
authors.lastname: Nagy-Vincze
authors.affiliation: Debreceni Egyetem, Orvos- és Egészségtudományi Centrum Belgyógyászati Intézet, Klinikai Immunológia Tanszék Debrecen Móricz Zsigmond körút 22. 4032.
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Griger
authors.affiliation: Debreceni Egyetem, Orvos- és Egészségtudományi Centrum Kardiológiai Klinika Debrecen.
authors.forename: Andrea
authors.initials: A
authors.lastname: Péter
authors.affiliation: Debreceni Egyetem, Orvos- és Egészségtudományi Centrum Onkológiai Tanszék Debrecen.
authors.forename: Csilla
authors.initials: C
authors.lastname: András
authors.affiliation: Debreceni Egyetem, Orvos- és Egészségtudományi Centrum Belgyógyászati Intézet, Klinikai Immunológia Tanszék Debrecen Móricz Zsigmond körút 22. 4032.
authors.forename: Katalin
authors.initials: K
authors.lastname: Dankó
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived / Q000494:pharmacology; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D001691:Biological Therapy / Q000379:methods; D002986:Clinical Trials as Topic; D003165:Complement System Proteins / Q000187:drug effects / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007155:Immunologic Factors / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects; D018908:Muscle Weakness / Q000209:etiology; D009220:Myositis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology* / Q000628:therapy; D000069283:Rituximab; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab; D003165:Complement System Proteins; C472181:efalizumab
keywords: TNF-alfa-gátlók; anti-TNF-alfa therapy; biological therapy; biológiai terápia; idiopathic inflammatory myopathies; idiopathiás inflammatorikus myopathiák; rituximab